Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
BRCA mutations
PARP inhibitors
adoptive immunotherapy
homologous recombination deficiency
immune checkpoint inhibitors
ovarian cancer
vaccines
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
14 07 2022
14 07 2022
Historique:
received:
03
06
2022
revised:
06
07
2022
accepted:
12
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Ovarian cancer is one of the most common gynecologic cancers and has the highest mortality rate of any other cancer of the female reproductive system. Epithelial ovarian cancer (EOC) accounts for approximately 90% of all ovarian malignancies. The standard therapeutic strategy includes cytoreductive surgery accompanied by pre- or postoperative platinum-based chemotherapy. Nevertheless, up to 80% of the patients relapse within the following 12-18 months from the completion of the treatment and then receive first-line chemotherapy depending on platinum sensitivity. Mutations in
Identifiants
pubmed: 35886427
pii: ijerph19148577
doi: 10.3390/ijerph19148577
pmc: PMC9317199
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
EMBO J. 2004 Oct 1;23(19):3874-85
pubmed: 15385968
Front Genet. 2015 Mar 20;6:96
pubmed: 25852742
Clin Genet. 2020 Jan;97(1):54-63
pubmed: 31099061
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Nat Cell Biol. 2017 Nov;19(11):1371-1378
pubmed: 29035360
Clin Cancer Res. 2009 Dec 1;15(23):7277-90
pubmed: 19934293
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10
pubmed: 18287062
Cancers (Basel). 2021 Mar 15;13(6):
pubmed: 33803954
J Clin Oncol. 2012 Jul 20;30(21):2654-63
pubmed: 22711857
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Biomedicines. 2016 May 03;4(2):
pubmed: 28536377
Cancers (Basel). 2017 Aug 22;9(8):
pubmed: 28829366
J Immunother. 2014 Apr;37(3):135-46
pubmed: 24598449
Clin Cancer Res. 2013 Sep 15;19(18):5003-15
pubmed: 23881923
Nature. 2016 Jul 20;535(7612):382-7
pubmed: 27443740
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Am Soc Clin Oncol Educ Book. 2019 Jan;39:185-195
pubmed: 31099635
Cancer Epidemiol. 2021 Dec;75:102045
pubmed: 34638085
Clin Cancer Res. 2007 May 1;13(9):2728-37
pubmed: 17473206
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Gynecol Oncol. 2014 May;133(2):362-9
pubmed: 24607283
Lancet Oncol. 2019 May;20(5):636-648
pubmed: 30948273
Lancet Oncol. 2015 Jan;16(1):87-97
pubmed: 25481791
Crit Rev Oncol Hematol. 2019 Feb;134:46-55
pubmed: 30771873
J Immunother Cancer. 2015 Mar 24;3:7
pubmed: 25806106
Clin Cancer Res. 2006 Sep 15;12(18):5503-10
pubmed: 17000686
Curr Opin Immunol. 2009 Apr;21(2):215-23
pubmed: 19327974
Hum Vaccin Immunother. 2012 Sep;8(9):1179-91
pubmed: 22906947
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Invest New Drugs. 2020 Feb;38(1):181-193
pubmed: 31650446
Ann Oncol. 2017 Mar 1;28(3):443-447
pubmed: 28057663
Gynecol Oncol. 2017 Dec;147(3):695-704
pubmed: 29037806
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
Curr Oncol Rep. 2018 Nov 13;20(12):94
pubmed: 30421009
Cell Rep. 2018 Apr 3;23(1):100-111
pubmed: 29617652
Nature. 2018 Aug;560(7716):122-127
pubmed: 30046110
Ann Oncol. 2016 Jun;27(6):1013-1019
pubmed: 26961146
Ann Oncol. 2022 Mar;33(3):330-339
pubmed: 35090748
J Thorac Oncol. 2016 Jul;11(7):964-75
pubmed: 27117833
Genes Dev. 2017 Feb 1;31(3):318-332
pubmed: 28242626
Proteomes. 2022 May 09;10(2):
pubmed: 35645374
Diagnostics (Basel). 2019 May 18;9(2):
pubmed: 31109041
J Adv Res. 2018 Mar 06;12:1-9
pubmed: 29988841
Cell. 2002 Mar 22;108(6):781-94
pubmed: 11955432
Lancet Oncol. 2014 Oct;15(11):1207-14
pubmed: 25218906
Crit Rev Oncol Hematol. 2016 Dec;108:73-85
pubmed: 27931843
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Adv Cancer Res. 2013;119:421-75
pubmed: 23870514
Drugs R D. 2020 Jun;20(2):55-73
pubmed: 32215876
Int J Mol Sci. 2021 Sep 10;22(18):
pubmed: 34575947
Clin Cancer Res. 2012 Oct 1;18(19):5449-59
pubmed: 22847809
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Ann Transl Med. 2020 Dec;8(24):1710
pubmed: 33490222
Nat Rev Cancer. 2011 Sep 23;11(10):719-25
pubmed: 21941283
J Pathol. 2013 Feb;229(3):422-9
pubmed: 23165508
Lancet Oncol. 2022 Apr;23(4):465-478
pubmed: 35298906
Oncotarget. 2017 Feb 28;8(9):15621-15631
pubmed: 28152503
Cancer Discov. 2017 Sep;7(9):984-998
pubmed: 28588062
Drugs. 2017 Apr;77(5):585-592
pubmed: 28247266
JAMA Oncol. 2019 Aug 01;5(8):1141-1149
pubmed: 31194228
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
J Clin Oncol. 2020 Apr 10;38(11):1164-1174
pubmed: 32073956
Ann Oncol. 2006 Oct;17(10):1568-77
pubmed: 17005631
Gynecol Oncol. 2015 Jun;137(3):386-91
pubmed: 25818403
J Immunother Cancer. 2016 Jun 21;4:34
pubmed: 27330807
Nature. 2001 May 17;411(6835):366-74
pubmed: 11357144
J Biomed Sci. 2017 Apr 4;24(1):26
pubmed: 28376884
Diagnostics (Basel). 2019 Aug 01;9(3):
pubmed: 31374917
Cell. 2006 Nov 17;127(4):709-20
pubmed: 17110331
Cell Mol Life Sci. 2016 Aug;73(15):2829-50
pubmed: 26791483
Expert Opin Ther Targets. 2021 May;25(5):329-333
pubmed: 34225539
Lancet Oncol. 2019 Oct;20(10):1409-1419
pubmed: 31474354
Cell Mol Life Sci. 2020 Jan;77(1):3-18
pubmed: 31748913
Clin Cancer Res. 2015 Apr 1;21(7):1574-82
pubmed: 25589624
Epigenetics. 2006 Jul-Sep;1(3):116-20
pubmed: 17786175
Crit Rev Oncol Hematol. 2017 Dec;120:43-51
pubmed: 29198337
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
Nature. 2018 Aug;560(7716):117-121
pubmed: 30022168
Cancer Discov. 2017 Jun;7(6):620-629
pubmed: 28242752
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42
pubmed: 17652518
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
Int J Gynecol Cancer. 2019 Jan 10;:
pubmed: 30630885
J Exp Med. 2009 Dec 21;206(13):3015-29
pubmed: 20008522
Nat Rev Mol Cell Biol. 2011 Feb;12(2):90-103
pubmed: 21252998
Int J Mol Sci. 2021 Nov 23;22(23):
pubmed: 34884434
Science. 2003 Oct 24;302(5645):643-6
pubmed: 14576434
Clin Cancer Res. 1995 May;1(5):501-7
pubmed: 9816009
Nat Rev Clin Oncol. 2019 Feb;16(2):81-104
pubmed: 30356138
Gynecol Oncol. 2019 Feb;152(2):243-250
pubmed: 30522700
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Gynecol Oncol. 2019 Aug;154(2):314-322
pubmed: 31204078
J Pers Med. 2020 May 21;10(2):
pubmed: 32455595
Anticancer Res. 2016 Oct;36(10):5031-5042
pubmed: 27798862